Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Tailored treatment strategies for CLL

Here, Danielle Brander, MD, of the Duke University School of Medicine, Durham, NC, discusses tailored treatment strategies for chronic lymphocytic leukemia (CLL), including the use of B-cell receptor signalling inhibitors, and the BCL-2 inhibitor venetoclax. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.